RU  UA  EN

Friday, 22 November

18:30
The advantages outweighed the risks: FDA officials back Pfizer jab for children over five in the United States
A US government panel has voted to recommend the Pfizer/BioNTech vaccine should to be given to children aged five to 11.

22:17
Third booster dose of COVID-19 vaccine: 50-fold jump in antibodies after a third shot in Israel
Israeli scientists have confirmed the high effectiveness of the third dose of the coronavirus vaccine.

14:27
Pfizer and AstraZeneca COVID-19 vaccines’ effectiveness against Delta variant: study results
Two doses of Pfizer or AstraZeneca coronavirus vaccineare highly effective against the Delta strain, which is now the dominant COVID-19 variant in the world.

11:33
Pfizer reacted to the report of death of a Ukrainian citizen after a COVID vaccination
The coronavirus vaccine manufacturer, Pfizer/BioNTech, reacted to the death of a 47-year-old Ukrainian a few hours after he received a shot of a Pfizer coronavirus vaccine on July 2, 2021.

20:54
BioNTech made a statement regarding the effectiveness of its COVID-19 vaccine against different coronavirus strains
The Pfizer-BioNTech coronavirus vaccine does not require any modifications to ensure the protection against new strains of COVID-19.This was stated in a statementpublished by BioNTech.

14:37
Ukraine shall receive additional 10 million doses of the Pfizer vaccine
Ukraine has signed a contract with the American pharmaceutical company Pfizer on the supply of additional 10 million doses of COVID-19 vaccine.

00:10
Pfizer summed up the results of vaccination for six months
The Pfizer/BioNTech COVID-19 vaccine was able to prove its effectiveness within six months vaccinating period.

07:12
Pfizer initiates phase 1 study of the novel oral antiviral therapeutic drug against COVID-19
The American company Pfizer Inc, which has created a vaccine against COVID-19, announced that it is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for SARS-CoV-2, the virus that causes COVID-19.